I have a complicated relationship with biotech stocks. I love the science, the unmet medical needs, and the possibility that one successful medicine can change both patients’ lives and a company’s value. I am less fond of waking up to discover that a clinical trial missed its primary endpoint and half my investment has evaporated before I have located the coffee. That is the biotech bargain. Investors are invited to study molecular targets, trial designs, competitive landscapes, safety profiles, and regulatory pathways. Then a press release arrives at 7:00 a.m. and reduces years of careful analysis to one merciless word: met or missed. This is why ACADIA Pharmaceuticals catches my attention. ACADIA, which trades under the ticker ACAD, does not fit neatly into the familiar small-biotech stereotype. It is not a pre-revenue company living from financing round to financing round while asking shareholders to remain patient for another eighteen months. It already sells two FDA-approved medic...
Whenever I hear someone ask what Apple will do after the iPhone, I think the question begins in the wrong place. It assumes Apple needs to invent another product as culturally dominant and financially powerful as the iPhone before the company can create its next trillion dollars of market value. I do not believe it does. Apple is no longer a company waiting for one device to save it. It is a platform spread across billions of active devices, supported by custom silicon, software, subscriptions, payments, wearables, health data and an extraordinarily loyal customer base. The iPhone remains the center of that system, but the next phase of Apple’s value may come from making every person inside the system worth a little more—not from discovering a completely new population overnight. As of September 14, 2026, Apple’s market capitalization was approximately $4.9 trillion. Adding another trillion would represent an increase of roughly 20%. That is a serious challenge, especially with the sto...